Skip to main content
. 2023 Jun 16;23:279. doi: 10.1186/s12886-023-03012-1

Fig. 2.

Fig. 2

Hazard ratio for incident cataracts in all patients, and in patients achieving LDL-C levels < 25 or < 15 mg/dL with alirocumab, compared with propensity score-matched patients from the placebo group. CI, confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol